Vasculitis & polymyalgia rheumatica
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
Methodological detailssystematic literature review, expert opinion, consensus through voting, anonymous level of agreement, Task force: 29 participants from 10 countries (physicians, a healthcare professional and a patient)
- Systematic literature review
- Expert opinion
- Consensus through voting
- Anonymous level of agreement
- Task force: 29 participants from 10 countries (physicians, a healthcare professional and a patient)
Recommendations
As issued by the authors
Management of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) should be based on shared decisions between patient and physician, recognising the need for urgent treatment of GCA to avoid ischaemic complications, and should aim at maximising health-related quality of life in both diseases.
The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage.
Comorbidities need to be considered when assessing disease activity and selecting treatment.
Original publication
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →